Intrahepatic cholangiocarcinoma (ICC) ranks among the deadliest cancers, with a 5-year survival rate of only 5-15% due to late diagnosis and lack of effective treatment. The discovery that receptor tyrosine kinase Fibroblast Growth Factor Receptor 2 (FGFR2) is genetically activated in >20% of ICCs, most commonly via FGFR2 gene fusions, is leading to a new therapeutic paradigm for a subset of patients with this disease. Indeed, early clinical trials with FGFR inhibitors (FGFRi) show significant anti-tumor efficacy, demonstrating true `oncogene addiction' to FGFR2, analogous to the role of EGFR mutations or ALK fusions in lung cancer. However, as in lung cancer, drug resistance is a vexing challenge: patients treated with BGJ398, the most clinically advanced FGFRi, usually progress within 6 months. In this Project, we aim to address key barriers to improving care of patients with FGFR2+ ICC. We will define mechanisms of resistance to FGFRi's, pr will provide evidence to support both combination strategies as well as the testing of a novel class of FGFR2 inhibitors in the clinic. We propose a multi-pronged strategy for impactful translational research that leverages serial tumor and liquid biopsies from three FGFRi trials, a series of patient-derived xenografts (PDX) and organoids, a genetically engineered mouse model, and novel FGFR2 inhibitors. We will systematically address the key barriers to more effective targeted therapy against FGFR2 in ICC: 1) the mechanism of FGFRi resistance, either due to acquisition of secondary FGFR2 mutations or activation of `bypass' signaling pathways, 2) identification of more effective FGFR2 inhibitors, including those that can target the kinase after it acquires resistance mutations, and 3) defining novel combination therapies to target bypass pathways to counter resistance and prolong initial response. We propose the following Specific Aims:
Aim 1. To identify and credential mutations causing FGFRi resistance in ICC.
Aim 2. To identify FGFR inhibitors that more effectively target FGFR2.
Aim 3. To develop combination strategies to overcome FGFR2-independent resistance mechanisms.

Public Health Relevance

The goal of this project is to develop new therapies for intrahepatic cholangiocarcinoma with genomic alterations that activate FGFR2 signaling. We will study the molecular basis for acquired resistance to FGFR targeting drugs and develop strategies to improve drug responsiveness and overcome resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA127003-11A1
Application #
9792057
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2007-04-01
Project End
2024-05-31
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
11
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ma, Siyuan; Ogino, Shuji; Parsana, Princy et al. (2018) Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biol 19:142
Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Aguirre, Andrew J; Nowak, Jonathan A; Camarda, Nicholas D et al. (2018) Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov 8:1096-1111
Hill, Margaret A; Alexander, William B; Guo, Bing et al. (2018) Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 78:4445-4451
He, Xiaosheng; Wu, Kana; Ogino, Shuji et al. (2018) Association Between Risk Factors for Colorectal Cancer and Risk of Serrated Polyps and Conventional Adenomas. Gastroenterology 155:355-373.e18
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Hu, Yang; Ding, Ming; Yuan, Chen et al. (2018) Association Between Coffee Intake After Diagnosis of Colorectal Cancer and Reduced Mortality. Gastroenterology 154:916-926.e9
Cao, Yin; Wu, Kana; Mehta, Raaj et al. (2018) Long-term use of antibiotics and risk of colorectal adenoma. Gut 67:672-678
Barry, Joseph D; Fagny, Maud; Paulson, Joseph N et al. (2018) Histopathological Image QTL Discovery of Immune Infiltration Variants. iScience 5:80-89

Showing the most recent 10 out of 590 publications